АНЕМИЯ КАК ПРЕДИКТОР ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

##plugins.themes.academic_pro.article.sidebar##

Published Apr 19, 2023
Download
pdf
Statistic
Vol. 2 No. 4 (2023): Journal of Integrated Education and Research

##plugins.themes.academic_pro.article.main##

Кушназаров Рустам Сафарович
врач-кардиолог центр РСНПМЦ Кардиологии Самаркандского регионального филиала, Узбекистан, г. Самарканд;
Рахматуллаев Акмал Акбарович
врач-кардиолог центр РСНПМЦ Кардиологии Самаркандского регионального филиала, Узбекистан, г. Самарканд;
Рузиева Амира Асроровна
врач-кардиолог центр РСНПМЦ Кардиологии Самаркандского регионального филиала, Узбекистан, г. Самарканд

Abstract

Несмотря на развитие медицины, во всем мире отмечается  непрерывный рост пациентов с (ХСН). Высокая заболеваемость и летальный исход от ХСН, не устранено по сей день, хотя существуют бесчисленное количество медикаментозных средств; руководств и рекомендаций по оптимальному использованию модернизаций, основанных  на принципах доказательной медицины [1]. Индустриально развитые страны имеют свои статистические данные по распространенности ХСН 0,34-2,43 % в общей популяции, среди  возрастной категории старше 65 лет частота ХСН превышает  3,6-13,8 %. Западноевропейские страны и США по частоте распространенности ХСН популяция представляет 0,14-0,57 % показатель, последний ежегодно удваивается [2]. Исследовательские данные ЭПОХА-ХСН (ЭПидемиологическое Обследование больныХ ХСН в реальной прАктике) указывают на частоту ХСН с I-IV функциональными классами (ФК) по классификации Ньюйоркской ассоциации сердца (NYHA) в России 10,83 % у женщин и 6,46 % у мужчин (в среднем 8,94 %) [3].

##plugins.themes.academic_pro.article.details##

How to Cite
Кушназаров Рустам Сафарович, Рахматуллаев Акмал Акбарович, & Рузиева Амира Асроровна. (2023). АНЕМИЯ КАК ПРЕДИКТОР ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ. Journal of Integrated Education and Research, 2(4), 86–93. Retrieved from https://ojs.rmasav.com/index.php/ojs/article/view/1029

References

  1. МсМurray JJ, Steward J. Epidemiolodgy, aetiolodgy, and prognosis of heart failure. Heart 2000; 83: 596-602.
  2. Rickenbacher P. Herzinsuffizienz: Epidemiologie, Patophysiologie. Swiss Med Forum 2001; 1/2: 4-9.
  3. Арутюнов Г. П., Кафарская Л. И., Савелов Н. А и др. Хроническая сердечная недостаточность: структурные и микробиологические изменения в толстой кишке. Тер архив 2007; 2: 31-7.
  4. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 2004; 10: S1-4.
  5. Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 2005;
  6. (Suppl 3): S13-21. 6. Tang Y-D, Katz SD. The prevalence of anemia in chronic heart failure and its impact on clinical outcomes. Heart Fail Rev 2008; 13: 387-92.
  7. Tang Y-D, Katz SD. Аnemia in chronic heart failure: prevalence, etiologie, clinical correlates, and treatment optiones. Circulation 2006; 113: 2454-61.
  8. Dallman PR. Iron Nutrition in Health and Disease. Eastleigh, UK: John Libbey & Co., 1996.
  9. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalizacion in patients with decompensated heart failure. Am J Cardiol 2003; 92: 625-8.
  10. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalizacion in adults with chronic heart failure. Circulation 2006; 113: 2713-23.
  11. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. JACC 2005; 45: 391-9.
  12. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112: 1121-7.
  13. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27: 1440-6.
  14. Nair D, Shlipak MG, Angeja B, et al. Association of anemia with diastolic dysfunction among patients with coronary artery disease in the Heart and Soul Study. Am J Cardiol 2005; 95: 332-6. 15. Felker GM, Shaw LK, Stough WG, O’Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006; 151: 457-62.
  15. Berry C, Norrie J, Hogg K, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 2006; 151: 1313-21.
  16. O’Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006; 113: 986-94.
  17. Anand IS, Rector T, Deswal A, et al. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 2006; 27 (Suppl 1): 485.
  18. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26: 2232-7.
  19. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110: 149-54.
  20. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. JACC 2001; 38: 955-62.
  21. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. JACC 2002; 39: 1780-6.
  22. Ghali JK, Anand IS, Abraham WT, et al. Randomized doubleblind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circilation 2008; 117: 526-35.
  23. Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25: 1021-8.
  24. 25. Datta BN, Silver MD. Cardiomegaly in chronic anemia in rats and man experimental study including ultrastructural, histometric, and stereologic observations. Lab Invest 1975; 32: 503-14. 26. Olivetti G, Quaini F, Lagrasta C et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia- induced cardiac hypertrophy in rats. Am J Pathol 1992; 141: 227-39.
  25. Levin A. The treatment of anemia in chronic kidney disease understandings in 2006. Curr Opin Nephrol Hypertens 2007; 16: 267-71.
  26. Collins AJ. The hemoglobin link to adverse outcomes. Adv Stud Med 2003; 3: S194-7.
  27. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002; 39(Suppl.1): S17-31.
  28. Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol. Dial Transplant 2000; 15(Suppl. 3): 14-8.
  29. Физиология человека. Под ред. Р. Шмидта и Г. Тевса. В 3 томах. М.: Мир 1996; 2: 313 с. 32. Takenaga K, Fukuma N, Seino Y, Takano T. A 69-year-old woman with congestive heart failure caused by myocardial ischemia and severe anemia. J Cardiology 2000; 36(3): 197-9.
  30. Davie NJ, Crossno JT, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: potential contribution of circulating progenitor cells (R1). Am J Physiol Lung Cell Mol Physiology 2003; [E pub a head of print].
  31. Bauer C, Kurtz A. Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol 1989; 51: 845-56.
  32. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989; 80: 299-305.
  33. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36.
  34. Volpe M, Tritto C, Testa U et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74: 468-73. 38. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. JACC 2004; 44: 63-7.
  35. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107: 223-5.
  36. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-4.